Company: MYGN
Filing Date: 2025-04-09
Form Type: DEF 14A
Source: 0000899923-25-000028
Chunk: 47

Company: MYRIAD GENETICS INC
Filing Date: 2025-04-09
Form: DEF 14A
Chunk 47
---
 April 30, 2025. (5) Mr. Verratti will succeed Mr. Raha as Chief Operating Officer effective April 30, 2025. Fiscal Year 2024 Financial Highlights During fiscal year 2024, we continued to make progress on our strategic growth plan. Some of our financial highlights during 2024 include the following: • Revenue increased 11% year-over-year to $838 million, driven by Pharmacogenomics revenue growth of 23% year-over-year as well as Prenatal and Hereditary Cancer revenue growth year-over-year of 17% and 11%, respectively. • GAAP operating loss was $(123.5) million while adjusted operating income 1 was $21.8 million, a year-over-year increase of $47.3 million compared to fiscal year 2023 adjusted operating loss of $(25.5). • GAAP net loss was $(127.3) million while adjusted EBITDA 1 was $40.4 million, an improvement of $51.9 million compared to fiscal year 2023 adjusted EBITDA of $(11.5) million. • GAAP loss per share was ($1.41) while adjusted EPS 1 was $0.14, an improvement of $0.41 over fiscal year 2023 adjusted EPS of $(0.27). Focusing on our longer-term growth and profitability, over the past two years, our revenue has increased at a compound annual growth rate of 11.1%, our adjusted operating income has increased by $54.6 million, and our adjusted EBITDA has increased by $61.6 million. The following tables show our total revenue, adjusted operating income (loss), and adjusted EBITDA in millions for fiscal years 2022, 2023, and 2024. 1 An explanation of the adjustments to our GAAP financial measures used in this proxy statement and a reconciliation of the adjusted financial measures to the comparable GAAP financial measures are included in Appendix A to this proxy statement. 30

Fiscal Year 2024 Business Highlights

In addition to our financial results during the 2024 fiscal year set forth above, some of our business highlights include:

• Acquired select assets from Intermountain Precision Genomics' laboratory business, including the Precise Tumor test, the Precise Liquid test, and a CLIA-certified laboratory.

• Ranked among Best Large Workplaces in Health Care by Fortune and achieved a Great Place to Work ® Certification for